MARKET ACCESS &
We have outstanding expertise on market access issues and the eligibility of innovative pharmaceuticals for reimbursement.
We advise pharmaceutical companies and service providers on all aspects of the pharmaceutical supply. Our advice comprises the regulations of prices under SGB V (price negotiations, reference prices, manufacturer discounts), possible arrangements via selective contracts, regional pharmaceutical contracts, measures steering prescription habits as well as reviews of commercial reasonableness.
A particular focus is placed on the regulation of prices under the Pharmaceutical Market Restructuring Act (AMNOG). Gerhard Nitz and Jörn Grotjahn have gained a multi-year experience in the context of benefit assessment by the Federal Joint Committee (G-BA), from negotiations of the reimbursement amount with the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) as well as from AMNOG arbitration proceedings and litigation proceedings.